Objective
Currently there are approximately 33.4 million people living with HIV-1 worldwide and it is estimated that every year AIDS claims about 2-3 million deaths while HIV-1 is responsible for an equal number of new infections. In spite of the advances in the fight against HIV-1 since the isolation of the virus in 1983, there is still no vaccine available for the prevention of HIV-1 infection, and so far the available therapies have failed to eradicate the virus. The use of animal models for the development of vaccines, testing of new antiviral drugs, and studies of pathogenesis has been invaluable. The presence of several barriers to HIV-1 replication in cells of many species narrows the species tropism of HIV-1 to humans and chimpanzees. The most widely used animal model for AIDS is the infection of Asian macaques by simian immunodeficiency virus (SIV) or simian-human immunodeficiency virus (SHIV) chimerae. The development of models in which the host animal can be infected with more HIV-1-like viruses is a worthy goal. Such a new animal model would be useful for studying viral pathogenesis and for testing antiviral therapies and vaccines. Here, we propose to study the host cell restriction factors that block the replication of HIV-1 in common marmoset cells, with the long term goal of developing a new animal model for HIV-1 infection using the common marmoset, a New World monkey, as a host animal.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology virology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antivirals
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-CIG
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MC-CIG - Support for training and career development of researcher (CIG)
Coordinator
28006 MADRID
Spain
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.